They are main ligands to the nuclear receptor FXR that has been shown to improve the lipid and glucose profile and has been repeatedly discussed as a putative drug target for the treatment of NAFLD [15]. Here, NR1H4 is linked to metabolic dysfunction-associated steatotic liver disease.